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Abstract
Current evidence suggests that the epithelial Na+ channel (ENaC) in the brain plays a
significant role in the development of hypertension. ENaC is present in vasopressin (VP)
neurons in the hypothalamus, suggesting that ENaC in VP neurons is involved in the
regulation of blood pressure. Our recent study demonstrated that high dietary salt intake
caused an increase in the expression and activity of ENaC that were responsible for the
more depolarized basal membrane potential in VP neurons. A known regulator of ENaC
expression, the mineralocorticoid receptor (MR), is present in VP neurons, suggesting
that ENaC expression in VP neurons is regulated by aldosterone. In this study, the effects
of aldosterone and corticosterone on ENaC were examined in acute hypothalamic slices.
Real-time PCR and Western blot analysis showed that aldosterone and corticosterone
treatment resulted in a significant increase in the expression of γENaC, but not α- or
βENaC, and that this expression was attenuated by MR and glucocorticoid receptor (GR)
antagonists. Moreover, chromatin immunoprecipitation demonstrated that the
aldosterone-MR complex directly interacts with the promoter region of the γENaC gene.
However, the treatment with aldosterone did not cause subcellular translocation of ENaC
toward the plasma membrane nor an increase in ENaC Na+-leak current. These results
indicate that expression of γENaC in VP neurons is induced by aldosterone and
corticosterone through their MR and GR, respectively; however, aldosterone or
corticosterone alone is not sufficient enough to increase ENaC current when they are
applied to hypothalamic slices in vitro.
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Introduction
Vasopressin (VP) is synthesized in magnocellular neurons located in both the
paraventricular (PVN) and the supraoptic (SON) nuclei of the hypothalamus and is
released from the neurohypophysis into the general circulation. VP neurons increase VP
secretion in response to hyperosmolality (Brimble and Dyball, 1977), hypovolemia
(Harris et al., 1975) and hypotension (Khanna et al., 1994) to produce antidiuretic and
pressor effects. The release of VP also occurs from the soma and dendrites of VP neurons
in the PVN to increase the activity of parvocellular neurons within the PVN that project
to the rostral ventrolateral medulla (Son and Stern, 2011). This action affects sympathetic
outflow and blood pressure (Dampney, 1994). VP neurons thus play a pivotal role in
coordinating neuroendocrine and autonomic responses to maintain cardiovascular
homeostasis. Because the release of VP depends largely on the pattern of neuronal
activity of their synthesizing neurons (Poulain and Wakerley, 1982; Cazalis et al., 1985),
factors modulating neuronal activity of these neurons are of great interest.
The non-voltage dependent and amiloride-sensitive epithelial Na+ channel
(ENaC) is a member of the degenerin/epithelial sodium channel (Deg/ENaC) superfamily
and is composed of three subunits (α, β, and γ) that form a highly selective Na+ channel
(Canessa et al., 1994). ENaC are present in aldosterone-sensitive epithelia that are
responsible for trans-epithelial Na+ transport, such as in epithelial cells that line the distal
part of the renal tubule, the distal colon, the duct of several exocrine glands, and the lung.
ENaC was also demonstrated in various structures in the brain, namely the SON, PVN,
subfornical organ, choroid plexus, and ependyma of the anterovental third ventricle
(Amin et al., 2005). The function of ENaC in the brain was studied in the choroid plexus
and VP neurons in the SON. In the choroid plexus, ENaC plays a role in Na+-transport
between blood and cerebrospinal fluid (CSF) , and thereby in regulation of CSF [Na+]
(Amin et al., 2009). In VP neurons, ENaC modulates the membrane potential by
mediating a Na+ leak current (Teruyama et al., 2012).
Several physiological studies showed that central administration of the ENaC
blocker, amiloride or its analog benzamil, attenuates sympathetic activity and
hypertension in several animal models of hypertension (Gomez-Sanchez and GomezSanchez, 1994, 1995; Nishimura et al., 1998; Keep et al., 1999; Nishimura et al., 1999;
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Wang and Leenen, 2002; Wang et al., 2003) and heart-failure (Ito et al., 2015). Because
the amounts of central administration of amiloride or benzamil used in these studies were
too small to be effective if they were administered in the general circulation, the effects
of amiloride or benzamil on sympathetic activity and hypertension were most likely
mediated by ENaC in the brain. While these studies provide little information regarding
the locations of ENaC action(s) in the brain, these studies indicate that abnormally
regulated ENaC in the brain plays a significant role in the development of hypertension.
Our recent studies showed that animals that consumed high dietary salt displayed
an enhanced ENaC current, which resulted in further depolarization of the basal
membrane potential of VP neurons (Sharma et al., 2017). These findings indicate that
high dietary salt intake enhances the expression and activity of ENaC, which in turn,
augments synaptic drive during hormonal demand by depolarizing the basal membrane
potential closer to the action potential threshold. Activation of ENaC, therefore, is a
powerful means to modulate hormone secretion according to physiological demands.
Furthermore, considering the role of VP in the cardiovascular homeostasis, ENaC in VP
neurons may have a major role in the regulation of blood pressure; however, the
mechanism underlying the regulation of ENaC activity in VP neurons remains mostly
unknown.
ENaC expression in epithelia is primarily regulated by the mineralocorticoid,
aldosterone, via the mineralocorticoid receptor (MR) (Renard et al., 1995; Escoubet et al.,
1997; Stokes and Sigmund, 1998a; Masilamani et al., 1999; MacDonald et al., 2000). The
MR was also found in various parts of the brain, namely the choroid plexus, ependyma,
neurons in the SON and PVN, the nucleus tractus solitarius, and in the subfornical organ
(van Eekelen et al., 1991; Amin et al., 2005; Han et al., 2005; Geerling and Loewy, 2009;
Teruyama et al., 2012). Of these MR-expressing structures, colocalization of the MR and
ENaC was found in magnocellular neurons of the SON and PVN, choroid plexus, and
ependyma (van Eekelen et al., 1991; Amin et al., 2005; Han et al., 2005; Geerling and
Loewy, 2009; Teruyama et al., 2012; Haque et al., 2015). The colocalization of the MR
and ENaC in VP neurons (Teruyama et al., 2012; Haque et al., 2015) suggests that ENaC
in VP neurons are also regulated by aldosterone. The present study that used acutely
prepared hypothalamic slices incubated with aldosterone, was conducted to examine the
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effects of aldosterone on the expression and activity of ENaC in VP neurons. This in vitro
approach allowed us to evaluate the effect of aldosterone on ENaC in VP neurons more
directly without the context of whole animal physiology.

Experimental procedures

Animals
Male Wistar rats (Harlan Laboratories, Indianapolis, IN) weighing between 260-300g
were used in the present investigation. Rats were housed on a 12:12-h light-dark cycle
and were allowed standard chow and water ad libitum. All protocols were carried out in
accordance with the National Institute of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional Animal Care and Use
Committees of Louisiana State University.

Acute hypothalamic slice preparation:
Rats were deeply anaesthetized with Ketamine-Xylazine (9:1, 100 mg/kg i.p.) and
perfused through the heart with cold artificial cerebral spinal fluid (ACSF), in which
NaCl was replaced by equiosmolar sucrose containing (in mM: 210 Sucrose, 3 KCl,
2.0 CaCl2, 1.3 MgCl2, 1.24 NaH2PO4, 25 NaHCO3, 0.2 ascorbic acid, and 10 D-glucose;
pH 7.4). The brain of each rat was removed and three coronal slices (500 μm), containing
the entirety of the SON and PVN, were collected using a vibrating microtome (Leica
VT1200; Leica, Mannheim, Germany). Other brain areas that are known to express
ENaC, namely the vascular organ of lamina terminalis (OVLT) (Miller and Loewy,
2013), area postrema (Miller et al., 2013), and subfornical organ (SFO) (Wang et al.,
2016), were not included. Slices were divided into two equal halves along the midline at
the third ventricle using microdissection scissors. Slice halves from the same side were
placed in the control group, while the other halves were placed in the treatment group.

In vitro incubation with corticosteroids
The hypothalamic slices were incubated on a plastic tray that consisted of wells with
nylon mesh bottom to hold individual slices in a glass beaker that was filled with 200 ml
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ACSF (in mM: 125 NaCl, 2.5 KCl, 1 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, 10 D-glucose,
2 CaCl2, 0.4 Ascorbic acid, pH of 7.3-7.4) with normal physiological osmolality and
[Na+] (~295 mOsm/kg and 151.24 mM, respectively). The normal physiological
osmolality of ACSF was chosen to avoid possible effects of higher osmolality on ENaC
expression, since intracerebroventricular (ICV) infusion of Na+-rich ACSF caused an
increase in hypothalamic aldosterone concentration in rats (Huang et al., 2008) and
vasopressin neurons are directly osmosensitive (Oliet and Bourque, 1993). The slices
were continuously oxygenated with 95% O2/ 5% CO2 gas and maintained at 34°C. The
incubation trays were placed at approximately half the depth of the beaker to ensure that
the slices were completely immersed throughout the experiment. Slices were incubated
for 6 hr with aldosterone, corticosterone, or vehicle. The incubation time of 6 hr was
chosen, because the pilot study showed 6 hr is the minimum duration that produced
significant changes in the amount of γENaC mRNA. In addition, a longer than 6 hr
incubation time did not allow us to conduct several-hour-long electrophysiological
experiments before the brain slices started to deteriorate. In some experiments, slices
were incubated for 30 min with the antagonist for the MR or glucocorticoid receptor
(GR) to block MR and GR prior to aldosterone or corticosterone application,
respectively. Following incubation, slices were trimmed along the dorsal portion of the
third ventricle lateral to the optic chiasm to minimize tissue that did not contain the PVN
and SON and to exclude the choroid plexus that is known to express ENaC subunits
(Amin et al., 2005). Trimmed slices were placed in RNALater (Qiagen, CA) and stored at
-20°C for later processing. Additional hypothalamic slices were fixed in 4%
paraformaldehyde with 0.1% picric acid in 0.15 M sodium phosphate buffer (pH 7.2-7.4)
and processed for immunocytochemistry.

Corticosteroids and antagonists:
Aldosterone and corticosterone were purchased from Sigma-Aldrich (St. Louis, MO).
Antagonists for MR and glucocorticoid receptors (GR) were RU-28318 (Tocris
Bioscience, Ellisville, MO) and RU-486 (Sigma- Aldrich, St. Louis, MO), respectively.
All compounds were dissolved into dimethyl sulfoxide (DMSO) to make stock solutions
and were further diluted in ACSF to reach the final concentration. RU-28318 used for

7

incubations was 2.5 µM, whereas that of RU-486 was 5 µM. The concentration of these
competitive antagonists was determined based on published reports that RU-28318 and
RU-486 competitively bind to the receptor with an affinity similar to that of the
mineralocorticoid (Janiak and Brody, 1988) and glucocorticoid (Schreiber et al., 1983).
The final concentration of DMSO in ACSF was 0.05% when aldosterone or
corticosterone was applied and 0.1% when MR or GR antagonists were applied in
addition to aldosterone or corticosterone.

Real-time PCR
Total RNA was isolated using TriReagent (Sigma-Aldrich, St Louis, MO) according to
the manufacture’s instructions, and tissue was homogenized using a tissue lyser (Qiagen,
Valencia, CA). Lysate was then treated with chloroform (ThermoFisher Scientific,
Waltham, MA) and centrifuged at 12,000 rpm for 15 min. Total RNA was precipitated
from the aqueous stage using isopropyl alcohol, and then washed with ethanol.
Precipitate was suspended in 20 μl RNAase-free water. The concentration and quality of
the isolated RNA were assessed using a spectrophotometer (NanoDrop 1000,
ThermoFisher Scientific, Waltham, MA). Isolated mRNA was reverse transcribed to
cDNA using oligo dT and M-MLV reverse transcriptase (Sigma-Aldrich, St. Luis, MO)
and used in real-time RT-PCR analysis. The ABI ViiA-7 sequence detection system
(ABI Applied Biosystem, Grand Island, NY) was used in conjunction with the SYBR
Select Master Mix (ABI Applied Biosystem, Grand Island, NY). All samples were
measured in triplicate and the two closest cycle threshold (Ct) values were averaged for
each sample.
The effect of the treatments was examined via the relative changes of the specific
target genes, which were calculated using the comparative cycle threshold method. For
each sample, the average Ct value of the target gene was subtracted by the housekeeping
(Cyclophilin B) gene to obtain the ΔCt value. The ΔCt values of the designated control
group were averaged and subtracted from each sample to generate the ΔΔCt value.
Relative change was then calculated for each sample by using the formula 2 - Δ ΔCt. All
results are shown as relative change in comparison to the control. The paired Student's t

8

test was used for comparison between treatment groups. Differences were considered to
be statistically significant at p <0.05.
Primers of selected genes were designed using Primer 3 software (Whitehead
Institute for Biomedical Research) and purchased from Sigma-Aldrich (St. Louis, MO).
All primer sequences were blasted on the National Center for Biotechnology Information
database to determine specificity of targeted gene. The sequences of the primer used are
listed in Table 1.

Semiquantitative immunoblotting
Total protein lysate samples were collected from above mentioned hypothalamic slice
preparation. The hypothalamic slices were incubated for 6 hr with 2.5 µM aldosterone or
vehicle, and were rinsed with cold PBS and placed in microcentrifuge tubes containing
250 µl of chilled complete lysis buffer. Lysis buffer was made fresh before each
experiment. Complete buffer contained: RIPA buffer (50 mM NaCl, 1.0% IGEPAL® CA630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0; Sigma-Aldrich, St.
Louis, MO), protease inhibitors (ProteoGuardTM EDTA-free protease inhibitor cocktail;
Takara Clontech, Mountain View, CA), 1 mM EGTA, 1 mM EDTA, and 1mM DTT.
Samples were briefly homogenized utilizing an electric tissue lyser (Qiagen, Valencia,
CA) and allowed to stand on ice for 10 min. Lysed samples were centrifuged for 20 min
at 12,000 rpm at 4°C. The pellet was discarded and the clear supernatant (total lysate)
was transferred to a clean tube to be stored at -20°C for later processing.
After protein concentration was determined (BCA kit; Pierce Chemical Co.,
Rockford, Illinois, USA), samples (15-20 µg of protein) were denatured by heating in 1x
Laemmli buffer (Bio-Rad) for 5 min at 95°C. Samples were resolved in a 4-15% SDSPAGE (Mini PROTEAN Precast Gels, Bio-Rad) gradient gel in Tris-glycine buffer (25
mM, 192 mM glycine, 0.1% SDS, pH 8.3; Bio-Rad) and transferred to a PVDF
membrane (Bio-Rad, Hercules, CA) under wet conditions (50V for 2 hr at 4°C). To
determine a successful transfer, the membrane was stained with Ponceau S solution
(Sigm-Aldrich, St. Louis, MO) for approximately 1 min. The membrane was destained
with 0.1 M NaOH for 30 sec followed by quick TBST wash (TBS-Tween; 50 mM Tris
base, 200 mM NaCl, 0.05% Tween 20). The membrane was blocked with 5% non-fat
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buffer (NFM; Bio-Rad, Hercules, CA) for 1 hr at room temp, and incubated overnight at
4°C with the selected primary antibody dissolved in 5% NFM buffer. A final
concentration for all ENaC primary antibodies was 1 µg/ml. Glyceraldehydye 3phosphate dehydrogenase (GAPDH; Abcam, Cambridge, MA) primary antibody was
used as a load control with a final concentration of 0.125 µg/ml. The next day, the
membrane was washed three times for 10 min each with TBST and incubated with the
horseradish peroxidase- conjugated (HRP) secondary antibody against the respective host
species (1:10,000, Goat- anti Rabbit – HRP; 1:10;000, Goat- anti Mouse, Bio-Rad)
dissolved in 5% NFM buffer at room temp for 2 hr followed by six TBST washes for 10
min each. Protein bands were detected through chemiluminescence reagents (ClarityTM
Western ECl Substrate Kit; Bio-Rad, Hercules, CA) and imaged utilizing a gel imaging
system (ChemiDocTM XRS+; Bio-Rad, Hercules, CA). Densitometric measurements were
obtained through ImageJ (NIH, Bethesda, MD).

Chromatin Immunoprecipitation (ChIP) and qPCR analyses
The rats (n=19) were deeply anesthetized with Ketamine:Xylazine (9:1; 100 mg/kg; i.p.)
and transcardially perfused with an artificial cerebrospinal fluid (ACSF) in which NaCl
was replaced by equiosmolar sucrose (in mM: 210 Sucrose, 3 KCl, 2 CaCl2, 1.3 MgCl2,
1.24 NaH2PO4, 25 NaHCO3, 0.2 ascorbic acid, and 10 D-glucose; pH 7.4). The brains
were removed and a hypothalamic block (4.5mm: 0.4gm) containing the SON and PVN
was made. Kidneys were also removed and blocked to be of equal weight as the brain.
The blocked tissues were ground and homogenized in 2 ml sodium phosphate buffered
saline (PBS; pH 7.2) containing 20 µl protease inhibitor (635673, Clontech, Mountain
View, CA). The homogenized samples were first cross-linked with 1% formaldehyde for
20 min at 37 ºC, and then lysed in SDS lysis buffer (1% SDS, 10mM EDTA, 50mM TrisHCl; pH 8.1) containing a protease inhibitor. The released nuclei were fractioned with
sonication to obtain a pool of DNA fragments of 300 to 500 bp in length. The sonicated
samples were divided into 3 individual aliquots. 60 µl of the protein A/G plus agarose
beads (sc-2003, Santa Cruz Biotechnology, Dallas, TX) were added to two tubes and
incubated for 2 hr at 4 ºC with gentle agitation to preclear the lysates. One tube
containing the lysate was used as the input control. The samples were centrifuged at
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2,000 rpm at 4 ºC for 5 min, and one of the two subsequent supernatants was used for
immunoprecipitation. Four different anti-MR monoclonal antibodies (rMR1-18 1D5,
MRN2 2B7, MRN3 3F10, and rMR365 4D6) were obtained from the Developmental
Studies Hybridoma Bank (Iowa City, IA). The supernatants were incubated with a
cocktail of the anti-MR antibodies at equal ratio (2.5 µg) for overnight at 4 ºC with gentle
agitation. After incubation with the antibodies, 120 µl of the protein A/G agarose beads
were added to both tubes (with Ab and without Ab) and incubated overnight at 4 ºC.
Subsequently, the samples were centrifuged at 1,000 rpm at 4 ºC for 5 min to remove the
supernatants and the remaining beads were washed five times in wash buffers. The
proteins were eluted using an elution buffer containing 1% SDS and 0.1M NaHCO3. The
protein-DNA crosslinks were reversed by heating at 65 ºC overnight with gentle
agitation. The DNA was recovered by phenol/chloroform extraction, precipitated with
ethanol, and dissolved in 25 µl TE buffer (pH 8.0). Input control, Ab, and no Ab samples
(2 µl each) were subjected to PCR with JumpStart REDTaq DNA polymerase (D0563,
Sigma- Aldrich, St. Louis, MO) to detect the MR-binding sites in the promoter region in
Scnn1g. The primer set (Forward 5’- GAAGGGTGAGATGGATTGGA- 3’ and Reverse
5’- GTAGGGGAAAGGGGGTAACA- 3’, chr1:191706400-191706675, 276 bp) was
specifically designed based on a previous study (Lombès et al., 1993). The following
PCR conditions were used: 95 ºC for 90 sec, 45 repetitions of the following cycles 95 ºC
for 30 sec, 60 ºC for 10 sec, 72 ºC for 60 sec, and final extension at 72 ºC for 5 min. The
PCR products from the input DNA, negative control (no Ab) and MR ChIP were
separated by agarose gel electrophoresis and visualized with ethidium bromide. For
quantitative PCR (qPCR) analysis, the total DNA concentrations of the samples were
measured using Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA) and
normalized so that equal amounts of DNA were amplified. The normalized product (2 µl)
was used for PCR with SYBR Select Master Mix (4472897, ABI Applied Biosystems,
Foster City, CA). The following PCR conditions were used: 95 ͦ C for 90 sec, 40
repetitions of the following cycles 95 ͦ C for 30 sec, 60 ͦ C for 60 sec, and final extension
at 72 ͦ C for 5 min. Results are reported as a percent change compared to the input control.

Immunocytochemistry
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Hypothalamic slices from six animals were processed concurrently under the same
conditions for immunocytochemical localization of ENaC subunits. The 500 µm thick
hypothalamic slices were cryoprotected by immersing in 50% glycerol in PBS for ~5 min
before mounting on a freezing microtome (SM2010R; Leica, Mannheim, Germany) and
sectioned at 40 µm. Slices were incubated with 5% normal goat serum in PBS containing
0.5% Triton X-100 (PBST) for 30 min at room temperature followed by the primary
antibodies directed against αENaC, βENaC, or γENaC at dilutions of 1:2,000, 1:500, and
1:4,000, respectively at 4°C with continuous gentle agitation for overnight. The rabbit
antibodies against the ENaC subunits were a generous gift from Dr. Mark A. Knepper
(National Institutes of Health, Bethesda, MD), and the characterizations of these
antibodies were previously described in great detail (Masilamani et al., 1999). The
hypothalamic slices were incubated with biotinylated goat-anti-rabbit IgG (1:500 in
PBST; Vector, Burlingame, CA) for 2 hr and with ABC complex (1:500 in PBST,
Vector, Burlingame, CA) for 1 hr. Subsequently, slices were incubated with
diaminobenzidine (DAB; Vector, Burlingame, CA) to visualize the immunoreactivity.
Slices were washed in PBST (3x5 min each) between each step. Finally, slices were
mounted on subbed slides, air-dried overnight, dehydrated in a series of alcohols, cleared
in xylene, and coverslipped with Permount (Fisher Scientific, Waltham, MA) mounting
medium. The hypothalamic slices containing the SON and PVN were digitally
photomicrographed in 12-bit intensity levels using a microscope (Nikon Eclipse 80i,
Tokyo, Japan) equipped with a digital camera (Nikon DS-QiMc, Tokyo, Japan).
For fluorescent confocal microscopy, the brain slices were incubated with a
secondary antibody (goat anti-rabbit) conjugated with DyLight 594 (Jackson
ImmunoResearch, West Grove, PA) for 4 hr at room temperature. The hypothalamic
slices were examined with a confocal microscope (Leica TCS SP8, Mannheim, Germany)
using a 63X/1.4 n.a. oil immersion objective lens. Confocal images (1024x1024; 0.232
µm/pixel) were acquired at the optical section thickness of 1 µm.

Electrophysiology
Brain slices were obtained as described in Acute hypothalamic slice preparation and
incubated with aldosterone or vehicle for 6 hr prior to the electrophysiological
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experiments. Whole-cell currents were recorded digitally at 20 kHz and filtered at 5 kHz
with a Digidata 1440A and an Axopatch 700B (Molecular Devices, Foster City, CA)
amplifier in conjunction with PClamp 10 software (Molecular Devices, Foster City, CA).
Magnocellular neurons in the SON were visually identified with a microscope (Olympus
BX50WI, Tokyo, Japan) equipped with a 40x water immersion lens (0.8 n.a., Olympus,
Tokyo, Japan). Recordings were taken using borosilicate electrodes (4-8MΩ resistance)
produced with a horizontal electrode puller (Model P-1000 Micropipette puller, Sutter
Instruments, Novato, CA). The intracellular solution (in mM: 140 K-Gluconate, 1 MgCl2,
10 HEPES, 10 CaCl2, 2 ATP (Mg2+), and 0.4 GTP (Na+), 11 EGTA, pH was adjusted to
7.25 with KOH, osmolality of 285 mOsm/kg H2O) contained 0.2% biocytin (SigmaAldrich, St. Louis, MO) to identify the cell type of the patched cell (Teruyama and
Armstrong, 2005, 2007). The extracellular solution (ACSF described above) was
saturated with 95% O2/5% CO2, and warmed to 33-34°C during the recordings. ACSF
contained picrotoxin and DNQX (100 and 10 µM, respectively) to suppress the synaptic
activity. The ENaC current was estimated from the benzamil-sensitive current that was
obtained from the difference in the steady state currents before and after the application
of benzamil (2 µM). Amiloride and its derivative benzamil are known potent blockers of
the degenerin/epithelial sodium channel superfamily of ion channels and the Na+/H+
exchanger (NHE) and the Na+/Ca2+ exchanger (NCX); however, benzamil at the dosage
used in this study (2 µM) is reasonably specific for ENaC as compared to the NHE and
NCX (Kleyman and Cragoe, 1988).

Statistics
Real-time PCR data were analyzed with the paired Student's t test for comparison
between treatment groups and control. For semi-quantitative immunoblotting,
densitometric measurements of bands were analyzed as comparison between
control and aldosterone values for individual animals. Differences were considered to
be statistically significant at p <0.05. Box-and-Whisker plot were used to represent
numerical data: the mean and median are represented by an open circle and a line,
respectively; the box extends to the quartiles of the data points; the whiskers extend to the
farthest data points.
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RESULTS

Dose-response relationship of aldosterone and ENaC subunit expression in the
hypothalamus
Dose-response relationships of aldosterone and ENaC subunit gene expression were
assessed by changes in the relative amount of mRNA for each of the subunits in response
to incubation for 6 hr with aldosterone at concentration of 0.1 (n=6), 0.5 (n=15), 2.5
(n=12), and 12.5 (n=6) µM. The expression of αENaC and βENaC did not change
significantly in response to aldosterone at any concentration tested; however, the
expression of γENaC was significantly higher on the side of hypothalamus that was
incubated with aldosterone at 2.5 (p = 0.003) and 12.5 (p = 0.038) µM compared to the
side of the hypothalamus incubated with vehicle only. When the responses were plotted
on log concentration of aldosterone, only the expression of γENaC showed a graded
dose-response (Fig. 1). Because the minimum concentration of aldosterone required to
induce a significant level of γENaC expression within 6 hr was 2.5 µM; subsequent
experiments were conducted using 2.5 µM aldosterone.

Aldosterone induces γENaC expression via the MR in the hypothalamus
The effect of aldosterone on the expressions of α-, β-, and γENaC subunits in the
hypothalamus was assessed by changes in the relative amount of mRNA for each of the
subunits. A significantly higher expression of γENaC was observed on the side of the
hypothalamic slice that was incubated with aldosterone compared to the side incubated
with vehicle only (Fig. 2A). In contrast to γENaC mRNA, no detectable effects of
aldosterone on the amount of αENaC or βENaC mRNAs were observed. To determine if
the effect of aldosterone on the expression γENaC was mediated by the MR, one side of
the hypothalamic slices was treated with a selective MR antagonist, RU-28318, prior to
the application of aldosterone. The relative amount of γENaC mRNA was significantly
lower on the side of the hypothalamic slices pretreated with the MR antagonist compared
to the aldosterone-only treated side suggesting that the MR antagonist prevented the
aldosterone induced γENaC expression (Fig. 2B). There was no detectable difference in
14

the relative amounts of αENaC and βENaC subunit mRNAs between the RU28318
pretreated and non-treated groups (Fig. 2B). In addition, the treatment with RU28318
alone did not affect the relative amounts of αENaC, βENaC, or γENaC subunit mRNAs
(Fig. 2C).
Semi-quantitative immunoblotting was also performed to assess whether the
abundance of ENaC subunit proteins changed in response to aldosterone. A distinct band
at the predicted molecular weight of 87 kDa and 85 kDa in protein extract from the
hypothalamus was detected by αENaC and γENaC antibodies, respectively (Fig. 3A). No
detectable band was labeled by the βENaC antibody in the protein extracted from the
hypothalamus (Fig. 3A), although a band at the predicted molecular weight of 88 kDa
was labeled by the βENaC antibody in the protein extract from the kidney cortex (data
not shown). The abundance of γENaC protein increased significantly on the side of
hypothalamic slice that was incubated with aldosterone; however, the abundance of
αENaC protein was unchanged (Fig. 3B).
Furthermore, Chromatin Immunoprecipitation (ChIP) was performed to assess
whether the aldosterone-MR complex directly regulated the expression of the γENaC
gene (Scnn1g). MR antibodies were used to precipitate fractions of DNA containing the
MR. Real-time PCR with a specific primer set detected the promoter region of Scnn1g in
the MR-immunoprecipitated DNA fractions from the hypothalamic block containing the
SON and PVN (Fig. 4).
Corticosterone induces γENaC expression through the GR in the hypothalamus
The effect of corticosterone on the expressions of the α, β, and γ ENaC subunits in the
hypothalamus was also assessed by determining the relative amount of mRNA for each
of the subunits. Incubation with corticosterone caused a significantly higher γENaC
subunit expression on that side of hypothalamic slice; however, no detectable effects
were observed in the expression of the αENaC and βENaC subunits (Fig. 5A).
Because the MR has a similar binding affinity for both mineralocorticoids and
glucocorticoids (Funder, 1995), experiments were performed to determine if the MR
mediated the effect of corticosterone on γENaC expression. One side of the hypothalamic
slices was pre-treated with the MR-antagonist, RU-28318, prior to the application of
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corticosterone, while the other side was treated with corticosterone only. No significant
difference was detected in the relative amounts of mRNAs for all ENaC subunits between
the corticosterone-only treated side of the hypothalamic slices and those treated with the
MR antagonist and corticosterone (Fig. 5B), indicating pretreatment with RU-28318
failed to block an increase in γENaC mRNA by corticosterone in hypothalamic slices.
Because the MR antagonist was unable to attenuate the effects of corticosterone
on γENaC expression, it was likely that corticosterone bound to the GR to induce γENaC
expression in the hypothalamus. To test this hypothesis, one side of the hypothalamic
slices was pre-treated with RU-486, a selective GR antagonist, prior to the application of
corticosterone, while the other side was treated with corticosterone only. The relative
amount of γENaC mRNA was significantly lower on the side of hypothalamic slices
treated with RU486 compared to those treated with corticosterone only; also, there were
no detectable differences in αENaC or βENaC expression between the treatment groups
(Fig. 5C). In addition, the treatment with RU486 alone did not affect the relative amounts
of αENaC, βENaC, or γENaC subunit mRNAs (Fig. 5D). Taken together, these results
indicate that GR antagonism was able to attenuate the effect of corticosterone on γENaC
expression.

Subcellular distribution of ENaC subunit immunoreactivity
In the region of the hypothalamus used for semi-quantification of the ENaC subunit
mRNAs and proteins in the present study, immunoreactivity of the ENaC subunits was
exclusively found in magnocellular neurons in the SON and PVN (Fig. 6 A&B). No
immunoreactivity of ENaC subunits was observed in the ependymal cell layers or in the
endothelium of blood vessels. Because our recent study showed that the αENaC labeling
was distinctively concentrated near the plasma membrane in neurons from animals that
were fed a high salt diet (Sharma et al., 2017), the effect of aldosterone on the subcellular
distribution of ENaC subunits immunoreactivity was also examined. Intense αENaC
immunoreactivity that was moderately concentrated towards the plasma membrane was
observed in most of the magnocellular neurons; however, no noticeable differences in
subcellular distribution of ENaC immunoreactivity occurred between control and
aldosterone treated hypothalamic slices from six different animals (Fig. 6C). Weak, but
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prominent, immunoreactivity of βENaC was observed in the cytoplasm of magnocellular
neurons (Fig. 6C). In contrast to βENaC immunoreactivity, γENaC immunoreactivity was
intense and fully filled the cytoplasm of magnocellular neurons (Fig. 6C).

Aldosterone did not change expression of vasopressin
In the kidney, VP promotes Na+ reabsorption by inducing the expression of β- and γENaC subunits (Djelidi et al., 1997; Ecelbarger et al., 2000; Nicco et al., 2001; Sauter et
al., 2006) and the translocation of intracellular pools of pre-existing ENaC subunits to the
apical membrane of the principal cells in the collecting duct (Schafer and Hawk, 1992).
The effect of aldosterone and corticosterone on the expression of VP was assessed to
evaluate possible effect of corticosteroid-induced VP on ENaC activity. Semiquantitative
PCR found that neither incubation with aldosterone nor corticosterone produced changes
in expression of VP in the hypothalamic slices (Fig. 7).

Effect of aldosterone on the benzamil-sensitive current
Of forty-five recorded VP neurons from 21 rats, 25 neurons were from the aldosteronetreated side, and 20 neurons were from the control side. From these recorded VP neurons,
12 (48%) recorded neurons from the aldosterone-treated sides and 6 (30%) recorded
neurons in the control sides showed a decrease (> 2.5 pA) in the steady state inward
current held at -80 mV in response to the application of benzamil (Fig. 8A). The
benzamil-sensitive current was obtained from the difference in the steady state currents
before and after the application of benzamil. The mean benzamil-sensitive current was
similar in VP neurons from both the aldosterone-treated (13.1 ± 3.8 nA) and control (11.7
± 5.4 nA: Fig. 8B) sides. The effect of aldosterone on cell size was assessed by
measuring the membrane capacitance of the recorded neurons. The mean whole cell
membrane capacitance did not differ between the aldosterone-treated (27.79 ± 2.55 pF)
and control (23.02 ± 2.41 pF) sides, indicating that a hypertrophy of VP neurons did not
occur in response to the aldosterone exposure (P=0.252; Fig. 8B). Subsequently, the
benzamil-sensitive current was normalized by the whole-cell capacitance, and the current
density (pA/pF) was obtained. The mean current density (0.47 ± 0.16 nA/pF) of VP
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neurons from the aldosterone treated hypothalamic slices did not differ from that (0.57 ±
0.18 nA/pF: Fig. 8C) in VP neurons from the control hypothalamic slices.

Discussion
Aldosterone directly induced the expression of γENaC via MR in VP neurons
The present study demonstrated that incubation of hypothalamic slices with aldosterone
resulted in induction of γENaC subunit expression, whereas αENaC and βENaC subunit
expression remained at basal levels. Antagonism of the MR attenuated the effect of
aldosterone on γENaC expression, indicating that aldosterone induced γENaC genomic
change via the MR in the hypothalamic slices. Moreover, the result from our ChIP
experiment indicated that the aldosterone-MR complex directly interacts with the
hormone responding element on the γENaC gene. Because the structures that express
ENaC were found only in magnocellular neurons in the PVN and SON in the
hypothalamic slices used in this study and because γENaC immunoreactivity was
identified prominently in the VP neurons in the SON and PVN in our previous study
(Teruyama et al., 2012), the aldosterone-MR mediated regulation of γENaC expression
most likely occurred specifically in VP neurons.
Corticosterone induces the expression of γENaC via GR in VP neurons
Another major finding of the present study is that corticosterone incubation resulted in a
significant increase in γENaC expression, similar to the expressional changes observed
subsequent to aldosterone incubation. Because corticosterone binds to both the GR and
MR with similar affinity (Beaumont and Fanestil, 1983; Krozowski and Funder, 1983;
Reul and de Kloet, 1985; Sheppard and Funder, 1987a; Sheppard and Funder, 1987b;
Funder, 1995), antagonists for MR and GR were used to elucidate which receptor was
activated to induce the γENaC expression. Antagonism of the MR was unable to prevent
this effect of corticosterone on γENaC expression; however, an antagonist of the GR did
attenuate induction of γENaC expression in the presence of corticosterone. These results
indicate that corticosterone preferentially binds to the GR rather than to the MR in VP
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neurons to induce γENaC expression.
Although plasma concentrations of glucocorticoids are substantially higher than
those of aldosterone (Holbrook et al., 1980), aldosterone is known to preferentially bind
to the MR in aldosterone sensitive-epithelia (Odermatt et al., 2001). Aldosterone
selectivity of the MR in the epithelia is achieved by inactivating intracellular
glucocorticoids through the glucocorticoid-inactivating enzyme, 11β–hydroxysteriod
dehydrogenase type 2 (11β-HSD2) (Gomez-Sanchez et al., 2005a), which converts
corticosterone into inactive metabolites (Funder, 1995; Naray-Fejes-Toth et al., 1998).
Thus, our present observation may be explained by our previous finding that 11β-HSD2
is expressed in the MR-expressing neurons in the SON and PVN (Haque et al., 2015).
Regulation of γENaC in VP neurons by aldosterone and corticosterone
Both the MR and GR belong to the nuclear receptor super family that act as transcription
factors regulating gene expression (Vallon et al., 2005; Ronzaud et al., 2007; Ackermann
et al., 2010). Upon hormone binding in the cytosol, the MR forms homodimers and
heterodimers with the GR and is translocated into the nucleus where it binds to the
hormone-responsive element of the target gene (Ou et al., 2001; Gekle et al., 2014). Since
the DNA binding domains of the MR and GR share approximately 94% amino acid
homology (Viengchareun et al., 2007), both the MR and GR are thought to bind the
common hormone-responsive elements in a sequence-specific manner to regulate some of
the same genes (Evans and Arriza, 1989). The present finding that corticosterone-GR
induced γENaC expression in a manner similar to that of aldosterone-MR in the
hypothalamus may be due to the activation of common hormone-responsive elements on

γENaC by the GR and MR.
Aldosterone alone does not cause increase in ENaC activity in VP neurons
Our recent study showed that the enhanced ENaC activity in response to high dietary salt
intake was associated with an increase in the expression of both βENaC and γENaC
subunits in the SON and the translocation of ENaC towards the plasma membrane
(Sharma et al., 2017). These changes in the expression of the βENaC or the subcellular
translocation of ENaC were not observed in the hypothalamic slices exposed to
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aldosterone in vitro. Therefore, other factors involving in induction of βENaC and
translocation of ENaC to fully activate ENaC in VP neurons were not activated in the
hypothalamic slices in media with aldosterone.
VP is known to induce the expression of βENaC subunits in the kidney (Djelidi et
al., 1997; Ecelbarger et al., 2000; Nicco et al., 2001; Sauter et al., 2006). Of the three
characterized VP receptor subtypes (V1a, V1b, and V2), VP appears to act through the
V2 VP receptor to induce gene expression of βENaC (Nicco et al., 2001) in the kidney.
VP also stimulates the translocation of intracellular pools of pre-existing ENaC subunits
to the apical membrane of the principal cells in the collecting duct promoting Na+
reabsorption in the kidney (Schafer and Hawk, 1992). VP neurons not only secrete VP at
nerve terminals in the neurohypophysis, but also release VP from their soma and
dendrites in the extracellular space of the SON and PVN (Landgraf and Ludwig, 1991;
Neumann et al., 1993; Ludwig, 1998). The presence of V2 receptors on VP neurons
suggests the possibility that βENaC in VP neurons could be regulated by the somatodendritic release of VP by mechanisms similar to their regulation in the nephron. Thus,
the absence of VP in the incubation media in this study may be the reason for the lack of
a change in βENaC expression and translocation of ENaC in VP neurons.

Effect of aldosterone on ENaC in the brain in vivo
Our recent study (Sharma et al., 2017) found that a NaCl deficient diet, which is known
to cause an increase in aldosterone in the general circulation (Frindt et al., 1990; Pacha et
al., 1993; Asher et al., 1996), did not cause a change in ENaC expression in the SON.
However, the NaCl deficient diet did cause an increase in αENaC mRNA in the kidney
known to occur in response to elevated aldosterone caused by such a diet (Renard et al.,
1995; Asher et al., 1996; Escoubet et al., 1997; Stokes and Sigmund, 1998b; Masilamani
et al., 1999; MacDonald et al., 2000). Instead, a high NaCl diet, which is known to
decrease circulating aldosterone, caused an increase in βENaC and γENaC mRNAs in the
SON (Sharma et al., 2017). This finding implies that plasma aldosterone has no effect on
ENaC expression in VP neurons. Despite the lipophilicity of steroids, aldosterone is
known to have a surprisingly poor penetration of the blood-brain barrier (BBB)
(Pardridge and Mietus, 1979; Funder and Myles, 1996; Parker et al., 2006). This also
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agrees with the finding in rats that subcutaneous infusion of aldosterone increased plasma
aldosterone level without significant changes in hypothalamic aldosterone content
(Huang et al., 2010). Therefore, the induction of γENaC expression in VP neurons by
plasma aldosterone in vivo is somewhat questionable.
One possible explanation for this is that aldosterone-MR-ENaC pathway in the
brain is regulated independently of the peripheral/renal pathway. A growing body of
evidence now suggests that aldosterone is synthesized in the CNS. The ability of brain
tissue to synthesize aldosterone was demonstrated in vitro (Gomez-Sanchez et al.,
2005b). Transcripts of aldosterone synthase (CYP11B2) were detected in various brain
regions including the hypothalamus (MacKenzie et al., 2000). The presence of
aldosterone synthase was detected by in situ hybridization in magnocellular neurons in
the SON (Wang et al., 2016). Together with the present finding that γENaC in the
hypothalamus is induced by aldosterone, these findings suggest that the expression of
γENaC in VP neurons is regulated by aldosterone that is synthesized locally.
Our previous studies demonstrated that high dietary salt intake caused an increase
in expression of γENaC in the SON of normotensive Wistar rats (Sharma et al., 2017) and
in the hypothalamus of salt-sensitive Dahl rats (Mills et al., 2018). If the increased
expression of γENaC is facilitated by local aldosterone, the high dietary salt intake must
affect the synthesis of aldosterone in the hypothalamus. Interestingly, ICV infusion of
Na+-rich ACSF caused in rats an increase in hypothalamic aldosterone concentration and
blood pressure, and both were prevented by ICV infusion of an aldosterone synthase
inhibitor (Huang et al., 2008). These findings indicate that aldosterone synthesis in the
hypothalamus is affected by the concentration of Na+ in the CSF. Because the
concentration of Na+ in the CSF increased due to high dietary salt intake in salt-sensitive
Dahl and spontaneously hypertensive (SHR) rats (Huang et al., 2004), it is possible that
the elevated expression of γENaC in the hypothalamus of salt-sensitive Dahl rats that
consumed high dietary salt (Mills et al., 2018) was mediated by an increased
hypothalamic aldosterone production. However, the same study did not find change in
CSF Na+ concentration in normotensive salt-resistance Dahl and Wistar Kyoto rats in
response to high dietary salt intake (Huang et al., 2004). Thus, it is somewhat
questionable that the high dietary salt intake induced γENaC expression in the SON of
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normotensive Wistar rats (Sharma et al., 2017) was mediated by an increased local
aldosterone synthesis that was upregulated by the increased CSF Na+ concentration.
Regardless of the change in the CSF Na+ concentration, the aldosterone induced γENaC
expression in the hypothalamus indicates that dietary salt intake influences the synthesis
of aldosterone in normotensive rats as well. More research needs to be conducted to
elucidate the mechanism underlying the regulation of hypothalamic aldosterone
production in response to physiological demand.

Limitations of this study
The physiological plasma concentration of aldosterone (<0.1 µM) did not induce gene
expression of ENaC subunits in in vitro hypothalamic slices. The concentration of
aldosterone used in this study was supra-physiological. For humans, this aldosterone
concentration in plasma would be above the pathological range (Mattsson and Young,
2006). The supra-physiological dose was probably required for aldosterone to penetrate
the relatively thick 500 µm hypothalamic slices without a functional vascular system.
One of the concerns for using a supra-physiological concentration of corticosteroids is
that these steroids may bind to other steroid receptors at that concentration. However, the
effects of aldosterone and corticosterone on γENaC expression was attenuated by both
MR and GR antagonists, respectively. In addition, the effect of corticosterone on γENaC
expression was not attenuated by a MR antagonist, suggesting that the high concentration
of the MR antagonist did not affect off-target receptors. Considering the presence of MRs
in VP neurons (Teruyama et al., 2012; Haque et al., 2015) and the direct interaction of
MR with the hormone responding element on the γENaC gene in the SON demonstrated
by the present ChIP experiment, it is reasonable to interpret that aldosterone induces the
expression of γENaC in VP neurons.

Physiological relevance and Conclusion
Several in vivo studies suggest that ENaC in the brain are activated by aldosterone. In
normotensive rats, ICV infusion of aldosterone increases blood pressure (Wang and
Leenen, 2002, 2003). In salt-sensitive Dahl rats, high-salt diet or ICV infusion of
aldosterone causes hypertension, but ICV infusion of a MR antagonist prevents the
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development of hypertension (Gomez-Sanchez et al., 1992). Intriguingly, ICV infusion of
amiloride or benzamil prevents salt-induced hypertension in salt-sensitive Dahl rats
(Gomez-Sanchez and Gomez-Sanchez, 1994; Wang and Leenen, 2002), as well as the
hypertension induced by ICV infusion of aldosterone in normal rats (Gomez-Sanchez and
Gomez-Sanchez, 1995). These findings suggest that aldosterone-mediated ENaC
activation in the brain is involved in the regulation of blood pressure.
ENaC subunits and MR in the brain are colocalized only in limited regions,
namely the SON, PVN, subfornical organ, choroid plexus, and ependyma of the
anterovental third ventricle (Amin et al., 2005; Teruyama et al., 2012; Haque et al.,
2015). In these brain structures, VP neurons in the PVN and SON are the only structures
that directly stimulate both endocrine and autonomic responses to maintain
cardiovascular homeostasis. In addition to the well-characterized endocrine role of VP on
antidiuretic and pressor effects, the somato-dendritic release of VP stimulates the activity
of parvocellular neurons that project to the rostral ventrolateral medulla (Son and Stern,
2011), thereby leading to increase in both sympathetic outflow and blood pressure
(Dampney, 1994).
ENaC in VP neurons mediate a steady state Na+ leak current that regulates the
basal membrane potential (Teruyama et al., 2012; Sharma et al., 2017). More depolarized
basal membrane potential observed in VP neurons in response to high dietary salt intake
was caused by increased ENaC expression and activity (Sharma et al., 2017). Therefore,
activation of ENaC raises the basal membrane potential closer to the action potential
threshold and consequently augments synaptic drive. Because the release of VP regulated
largely by the frequency and pattern of action potential firing in their synthesizing
neurons (Poulain and Wakerley, 1982; Cazalis et al., 1985), ENaC activity in VP neurons
could directly influence the release of VP and autonomic responses. Thus, the
physiological conditions that require VP, such as an excess dietary salt intake, may
promote release of VP through ENaC activation.
The present study identified a direct involvement of aldosterone and
corticosterone on γENaC expression in VP neurons via the MR and GR, respectively.
Thus, aldosterone and corticosterone are likely involved in activation of ENaC in VP
neurons. However, aldosterone itself is not sufficient to induce activation of ENaC in VP
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neurons, as neither induction of βENaC subunits nor translocation of ENaC to the plasma
membrane were observed after incubation with aldosterone. Therefore, the mechanism
underlying the regulation of ENaC activity in VP neurons remains largely unknown.
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Figure legends

Figure 1. Dose-response relationship of aldosterone and the expression of ENaC
subunits. Semi-log plots of changes in the relative amount of ENaC subunit mRNA in
the hypothalamus in response to different concentration of aldosterone. The expression of
αENaC and βENaC did not change significantly at any concentration tested; however,
the expression of γENaC was significantly higher on the side of hypothalamus that were
incubated with aldosterone at concentrations higher than 2.5 µM compared to the side of
the hypothalamus incubated with vehicle only. Data are shown as the means ± SE.

Figure 2. The effect of aldosterone on ENaC subunit expression in hypothalamic
slices
A. No significant difference in the relative amounts of αENaC and βENaC subunit
mRNAs was identified between the aldosterone incubated and control side of
hypothalamic slices; however, only the aldosterone incubated side had a significantly
greater amount of γENaC subunit mRNA (*p<0.003). B. No significant differences in
αENaC and βENaC subunit expression occurred between the sides of the hypothalamic
slices that were pre-incubated with and without RU-28318, respectively; however, the
side of the hypothalamic slices that was not pre-incubated with RU-28318 had a
significantly higher γENaC subunit expression compared to the side pre-incubated with
MR antagonist, RU-28318 (**p<0.034). C. No significant differences in αENaC, βENaC,
or γENaC subunit expression observed between the sides of the hypothalamic slices that
were incubated with and without RU-28318.

Figure 3. The effect of aldosterone on ENaC subunit proteins abundance in
hypothalamic slices
A. Immunoblots showing the effect of aldosterone on the abundance and molecular
weight of each ENaC subunit in the hypothalamic slices from 7 different animals. For
each blot, each lane was loaded with the protein extract from a side of hypothalamic
slices from an individual animal. The first seven lanes represent the side of the
hypothalamic slice that were treated only with vehicle, whereas the following seven lanes
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represent the corresponding other side of slices that were treated with aldosterone.
Antibodies against αENaC, γENaC, and GAPDH detected a single band at the correct
molecular mass at approximately 87, 85, and 37 kDa, respectively: however, no
detectable band was labeled with βENaC antibody in the protein extract from the
hypothalamus. B. Densitometric measurements of each band of αENaC and γENaC
immunoblot from the side of hypothalamic slice that were treated with aldosterone
and the other side of hypothalamic slices that were treated with vehicle only. A line
connects data points from the same animal. The treatment with aldosterone resulted in
no change in the band density of αENaC immunoblot; however, caused a significant
increase in the density of γENaC immunoblot.

Fig. 4. Chromatin Immunoprecipitation (ChIP) with MR antibody
A. Schematic representation of the genomic structure of Scnn1-g and the relative position
of the primer set used for ChIP experiments. The 13 exons of Scnn1-g are indicated with
vertical lines and boxes. B. Gel image of MR-ChIP experiment using chromatins
prepared from hypothalamic region of a rat brain and kidney. The DNA from input
control (n=19), immunoprecipitates with anti-MR antibody (Ab+, n=19), and negative
controls (Ab-, n=19) were used for PCR amplification. C. The relative amount of
immunoprecipitated DNA from Ab- and Ab+ was further analyzed with qPCR. Shown are
the relative values of the immunoprecipitates compared to the input control.

Fig. 5. The effect of corticosterone on ENaC subunit expression in hypothalamic
slices
A. No significant differences in the relative amounts of αENaC and βENaC subunit
mRNAs occurred between the respective sides of the hypothalamic slices that were
incubated with and without corticosterone, respectively; however, the sides that were
incubated with corticosterone had a significantly higher γENaC subunit expression
compared to those sides incubated with vehicle only (*p<0.007). B. No significant
differences in αENaC, βENaC, or γENaC subunit expression occurred between the sides
of the hypothalamic slices that were pre-incubated with and without MR antagonist, RU28318, respectively. C. No differences in αENaC and βENaC subunit expression
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occurred between the hypothalamic slices that were pre-incubated with and without GR
antagonist, RU486, respectively; however, the hypothalamic slices that were not preincubated with RU486 had a significantly higher γENaC subunit expression compared to
those pre-incubated with RU486 (**p<0.037). D. No significant differences in αENaC,
βENaC, or γENaC subunit expression observed between the sides of the hypothalamic
slices that were incubated with and without RU486.
Fig. 6. Immunocytochemical localization of γENaC in the hypothalamic slices
A. Immunoreactivity to γENaC was exclusively found in the magnocellular neurons in
both the SON and PVN. Although a limited number of neurons located in the area
between the SON and PVN were also immunoreactive to γENaC; no other prominent
immunoreactivity was found within the hypothalamic slices. B. In the SON,
immunoreactivity to γENaC was exclusively found in the magnocellular neurons. C.
Confocal microscopy of αENaC, βENaC, and γENaC immunoreactivities in
magnocellular neurons in the SON from hypothalamic slices that were treated with
aldosterone (bottom panels) and vehicle only (CTRL; top panels). The αENaC
immunolabeling within neurons was moderately concentrated towards the plasma
membrane; no noticeable differences in subcellular distribution of αENaC
immunoreactivity occurred between control and aldosterone treated hypothalamic slices.
Weak but prominent immunoreactivity of βENaC was observed in the cytoplasm. Intense
γENaC immunoreactivity fully filled the cytoplasm.
of NaCl deficient and control groups are mainly dispersed in the cytoplasm. No
noticeable differences in subcellular distribution of βENaC or γENaC immunoreactivity
occurred between control and aldosterone treated hypothalamic slices. 1 µm optical
section. Scale bars: 500 µm in A; 100 µm in B; and 50 µm in C.

Fig. 7. The effect of corticosteroids on VP expressions in hypothalamic slices
A. No significant differences occurred in the relative amounts of VP mRNA identified
between the aldosterone and vehicle only incubated sides of the hypothalamic slices. B.
No significant differences occurred in the relative amounts of VP mRNA identified
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between the sides of hypothalamic slices that were incubated with and without
corticosterone.

Fig. 8. The effect of aldosterone on benzamil-sensitive current. Aa. An example of
the effect of benzamil on the steady state current in a VP neuron. The steady state current
was measured in voltage clamp while the cell was held at -80 mV. Ab. Brief
hyperpolarizing pulses (15 mV, 200 ms) were injected every 5 s to monitor the input
resistance of the cell. Bath application of benzamil (2 μM) reduced the resting inward
current and decreased conductance by approximately 1.5-fold. A benzamil sensitive
current was obtained by changes in the steady state current in response to its application.
B. The mean benzamil-sensitive current did not differ in VP neurons from the
aldosterone-treated and control sides. C. The mean whole cell membrane capacitance of
VP neurons did not differ between the aldosterone-treated side and that from the control
sides. D. There was no difference in the mean benzamil sensitive current density in VP
neurons between the aldosterone-treated side and control sides.
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Table

Table 1.

Gene

Primer Sequence

Amplicon
Size

αENaC

F 5'-CCCAAGGGAGTTGAGTTCTG-3'

76 bp

R 5'-AGGCGCCCTGCAGTTTAT-3'
βENaC

F 5'-GGACCAGAGCTAAATATCACC-3'

78 bp

R 5'-CGGTAGTTGAACTCTTGGAAGTAGA3'
γENaC

F 5'-CCAGTACAGCCAGCCTCTG-3

91 bp

R 5'CTGGTACAACTGGTAGTAGCAATACAT3'
VP

F 5'-CACCTATGCTCGCCATGAT-3'

299 bp

R 5'-GCTTCCGCAAGGCTTCT-3'
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p=0.037

*

Cort
+
RU486

Cort

γENaC

n=6

1.0

1.0

n=6

2.0
1.0

Cort
+
RU486

n=6
1.5

n=8

γENaC

3.0

n=5

n=8

Cort
+
RU28318

βENaC

n=n

Vehicle

0.6

4.0

1.0

Cort

1.0

4.0

n=6

n=12

1.8

4.0

2.0

p=0.007

γENaC

βENaC

0.6
Cort

γENaC

2.0

1.0

1.4

Cort
+
RU28318

mean relative change

n=11

n=12

αENaC

1.8

1.0

βENaC

1.0

1.0

0.5

mean relative change

2.0

n=6

n=n

0.5
RU486

Vehicle

RU486

0.5
Vehicle

RU486

Vehicle

A

B
PVN
SON

C
CTRL

Aldo

αENaC

βENaC

γENaC

2.0
mean relative change

B

VP

1.5
1.0
0.5
0

n=10
Aldo

VP

2.0

n=12
Control

mean relative change

A

1.5
1.0
0.5
0

n=7
Cort

n=8
Control

A
a

b
-80

pA

-100

no Benzamil

-120

1s
2 μM Benzamil

-140
0

B

50

Membrane capacitance
(pF)

S

100

C

50

40

40

30

30
n=12
n=n

n=6

10

0

0

CTRL

D

Benzamil sensitive
current density (pA/pF)

1.5
1.0

20

10
Aldo

Benzamil

150

Benzamil sensitive
current (pA)

50

20

10 pA

0.5
n=12

Aldo

n=6

CTRL

0

n=12

n=6

Aldo

CTRL

